[{"address1": "Maxim 1", "address2": "2 Parklands Way Holytown", "city": "Motherwell", "zip": "ML1 4WR", "country": "United Kingdom", "phone": "44 14 1433 7557", "website": "https://tcbiopharm.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.", "fullTimeEmployees": 60, "companyOfficers": [{"maxAge": 1, "name": "Mr. Bryan L. Kobel", "age": 44, "title": "CEO & Director", "yearBorn": 1979, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Martin E. Thorp", "age": 71, "title": "CFO & Director", "yearBorn": 1952, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Camarra", "title": "Executive Vice President of Communications", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lauren  Bor Ph.D.", "title": "Head of Commercial Development Division", "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 1.05, "open": 1.06, "dayLow": 1.03, "dayHigh": 1.1482, "regularMarketPreviousClose": 1.05, "regularMarketOpen": 1.06, "regularMarketDayLow": 1.03, "regularMarketDayHigh": 1.1482, "beta": 0.26, "forwardPE": -0.22608696, "volume": 183506, "regularMarketVolume": 183506, "averageVolume": 855761, "averageVolume10days": 522960, "averageDailyVolume10Day": 522960, "bidSize": 1000, "askSize": 2900, "marketCap": 2523560, "fiftyTwoWeekLow": 0.85, "fiftyTwoWeekHigh": 826.0, "priceToSalesTrailing12Months": 0.8838464, "fiftyDayAverage": 1.70834, "twoHundredDayAverage": 66.15896, "currency": "USD", "enterpriseValue": 6563161, "profitMargins": -0.54244, "floatShares": 4595539, "sharesOutstanding": 2426500, "sharesShort": 207533, "sharesShortPriorMonth": 53132, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.0855, "heldPercentInsiders": 0.00145, "heldPercentInstitutions": 0.10235, "shortRatio": 0.12, "shortPercentOfFloat": 0.0855, "bookValue": 6.922, "priceToBook": 0.15024559, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1688083200, "earningsQuarterlyGrowth": -0.31, "netIncomeToCommon": -1548782, "trailingEps": -72.08, "forwardEps": -4.6, "enterpriseToRevenue": 2.299, "enterpriseToEbitda": -0.598, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "TCBP", "underlyingSymbol": "TCBP", "shortName": "TC BioPharm (Holdings) plc", "longName": "TC Biopharm (Holdings) Plc", "firstTradeDateEpochUtc": 1644589800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "ef544858-646b-3e8d-bcb0-2aed3539a593", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.04, "targetHighPrice": 140.0, "targetLowPrice": 140.0, "targetMeanPrice": 140.0, "targetMedianPrice": 140.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 1918522, "totalCashPerShare": 0.331, "ebitda": -10981032, "totalDebt": 2450411, "quickRatio": 0.952, "currentRatio": 1.086, "totalRevenue": 2855202, "debtToEquity": 122.089, "revenuePerShare": 29.639, "returnOnAssets": -0.67006, "returnOnEquity": -1.02366, "freeCashflow": -9896973, "operatingCashflow": -12186514, "earningsGrowth": -0.868, "grossMargins": 1.0, "operatingMargins": -4.0933, "financialCurrency": "GBP", "trailingPegRatio": null}]